April 17, 2018, 10:00 EST | 15:00 GMT | 16:00 CET
Current metabolite identification (MetID) scientists face MASSive exSPECtations—they are required to detect and identify metabolites with increasing efficiency despite shrinking analytical group sizes, pressure to perform more diverse activities, increased outsourcing of work, and slow, tedious, and error-prone methods. As a result analysts are left with much less time to devote to complex MetID projects, while being expected to streamline existing analytical procedures.
Watch this webinar to see how ACD/Labs' MS tools can ensure you meet your own MASSive exSPECtations in MetID! We'll discuss our industry leading MS MetID software tools, which will enable you to meet your challenges while promoting your projects in an informatics environment, proliferating your MetID data, and making informed decisions.
Enter your contact info to watch the webinar today!
In this webinar you will learn how to use ACD/Labs MS analysis software to:
Dr. Edward Milton (Application Scientist) obtained his Ph.D. from the University of St. Andrews in Scotland, where he studied palladium-catalyzed cross-coupling reactions as building blocks for pharmaceuticals. Following St. Andrews, he moved onto a Postdoctoral Researcher role at Pfizer in Sandwich, UK; here he concentrated on nickel-catalyzed cross-coupling reactions and medicinal chemistry. He then served as a Synthetic Chemist working on a variety of different projects for a CRO laboratory at BioCity in Nottingham, UK. Edward joined ACD/Labs 4 years ago and is currently focusing on ACD/Labs' MetID solutions.
Dr. Richard Lee (Senior Manager, Core Capability & Technology) obtained his Ph.D. from McMaster University in Canada, where his area of study focused on strategies for metabolite identification and metabolomics studies. From McMaster, he moved on as a Scientist at the Centre of Probe Development and Commercialization "CPDC" in Hamilton, Ontario, which developed radiopharmaceuticals as imaging agents and therapeutics for oncology. In this capacity, he was involved in a number of initiatives, acting as project leader and technical leader for radiopharmaceuticals candidates, which were ultimately approved for clinical use by Health Canada and the FDA. He has been with ACD/Labs for the past 5 years and has been responsible for the development of ACD/Labs' MetID solutions since their inception.